IPO Previews For The Week

With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

  • MOBILE GLOBAL ESPORTS INC. (NASDAQ:MGAM) becomes publicly listed starting on 2022-07-26. The company has a price range set between $4.0 and $5.0 with a 180-day lockup period. MOBILE GLOBAL ESPORTS INC. will be offering 1,500,000.00 shares at a per-share value of $4.5.

What Are IPOs?

An initial public offering, or IPO, is the transitional process of a private company deciding to go public and offer shares to investors on an exchange. Typically, IPOs offer companies the ability to build capital. Before a company becomes publicly listed, it must meet SEC requirements and work with investment banks through audits to determine pricing, offering date, and other important data points before the offering.

Companies and investment banks will work to establish a price range that the stock is expected to sell between. This is known as an offering range. Once a company goes public, its stock comes with an opening price. The insider lock-up period is usually a set number of days after an IPO where company insiders, or employees with a 10% or higher stake in their company, cannot sell shares.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Asian Markets Mixed, Europe Trades Lower Along With Crude and Gold – Global Markets Today While US Was Sleeping

On Tuesday, September 5, the U.S. markets ended in red. Dow fell due to higher Treasury yields, but a boost in energy stocks limited the losses. U.S. Treasury yields climbed as strong economic data and comments from Fed Governor Christopher Waller indicated no immediate need for rate changes.

ADIV

Read More

Cytokinetics’ Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst

Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed as a distinctive therapy for Hypertrophic Cardiomyopathy.

AZN